Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.46 |
| ▸ | RAF1 | P04049 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16025568 | 0.89 | LRRK2 (0.46) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025577 | 0.89 | LRRK2 (0.46) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025749 | 0.88 | LRRK2 (0.47) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025748 | 0.87 | LRRK2 (0.44) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025716 | 0.86 | LRRK2 (0.49) | LRRK2 | |
| SCHEMBL17430375 | 0.86 | LRRK2 (0.48) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025837 | 0.85 | LRRK2 (0.41) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025564 | 0.85 | LRRK2 (0.41) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025529 | 0.84 | LRRK2 (0.42) | LRRK2RAF1BRAFSMG1MTOR | |
| SCHEMBL16025821 | 0.83 | LRRK2 (0.45) | LRRK2RAF1BRAFSMG1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | LRRK2 1/4885RAF1 361/4885BRAF 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.